Syntarga B.V., a Nijmegen, Netherlands-based biopharmaceutical company, has received an investment of undisclosed amount from PPM Oost.
Syntarga, a spin off from Radboud University Nijmegen, is focused on developing a technology for linking antibodies to cancer drugs. The combination of antibody and cancer drug is also called “Antibody Drug Conjugate (ADC)”.
Arnhem and Enschede-based PPM Oost invests in promising companies that have the potential to contribute to the economic development of the Eastern Netherlands. The volume of its fund amounts to over € 100m.
FinSMEs
28/11/2010